Observational cohort study: deprivation and access to anti-dementia drugs in the UK

被引:51
|
作者
Cooper, Claudia [1 ]
Lodwick, Rebecca [2 ]
Walters, Kate [2 ]
Raine, Rosalind [3 ]
Manthorpe, Jill [4 ]
Iliffe, Steve [2 ,5 ]
Petersen, Irene [2 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Res Dept Primary Care & Populat Hlth, London, England
[3] UCL, Dept Appl Hlth Res, London, England
[4] Kings Coll London, Social Care Workforce Res Unit, London, England
[5] UK Dementias & Neurodegenerat Dis Res Network, London, England
关键词
dementia; healthcare disparities; cholinesterase inhibitor; older people; SOCIOECONOMIC-STATUS; DEMENTIA; CARE; POPULATION; PREVALENCE; PERIODS; LEVEL;
D O I
10.1093/ageing/afv154
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: UK National Dementia Strategies prioritise fair access to dementia treatments for the whole population. We investigated for the first time inequalities in NHS national dementia prescribing and how they have varied between UK countries and over time. Method: we investigated the association between Townsend deprivation score and anti-dementia drug prescribing in 77,045 dementia patients from UK primary care records from 2002 to 2013. Results: we included 77,045 patients with recorded dementia diagnosis or anti-dementia drug prescription. Least deprived patients were 25% more likely to be initiated on anti-dementia drugs than the most deprived (adjusted incidence rate ratio 1.25, 95% confidence interval 1.19-1.31). This was driven by data from English practices where prescribing rates were consistently lower in more deprived patients compared with Scotland, Northern Ireland and Wales, where prescribing was not related to deprivation quintile. Compared with English practices, anti-dementia medication was prescribed more often in Northern Irish (1.81, 1.41-2.34) and less in Welsh practices (0.68, 0.55-0.82), with a trend towards more prescribing in Scottish practices (1.14, 0.98-1.32). Drug initiation rates were also higher in younger people and men. Conclusion: four years after the English National Dementia Strategy, there is no evidence that the Strategy's key objective of reducing treatment inequalities is being achieved. Higher overall anti-dementia drug prescribing in Scottish and Northern Irish practices, and differing clinical guidelines in Scotland from other UK countries might explain greater equality in prescribing in these countries. Strategies to offer treatment to more deprived people with dementia in England are needed.
引用
收藏
页码:148 / 154
页数:7
相关论文
共 50 条
  • [22] Effect of anti-dementia drugs on LPS induced neuroinflammation in mice
    Tyagi, Ethika
    Agrawal, Rahul
    Nath, Chandishwar
    Shukla, Rakesh
    LIFE SCIENCES, 2007, 80 (21) : 1977 - 1983
  • [23] Anti-dementia drugs and hippocampal-dependent memory in rodents
    Yuede, Carla M.
    Dong, Hongxin
    Csernansky, John G.
    BEHAVIOURAL PHARMACOLOGY, 2007, 18 (5-6): : 347 - 363
  • [24] Drug Therapy for Patients with Alzheimer's Dementia using Anti-dementia Drugs
    Hausner, Lucrezia
    Froelich, Lutz
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (03) : 152 - 156
  • [25] Anti-Dementia Drugs and Hepatotoxicity-Report of Two Cases
    Hirono, Haruka
    Watanabe, Kazuhiko
    Hasegawa, Katsuhiko
    Hiroyasu, Kazuhiko
    Shibasaki, Koichi
    Ohkoshi, Shogo
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2018, 12 (03) : 261 - 263
  • [26] CO-ADMINISTRATION OF ANTIPSYCHOTICS AND ANTI-DEMENTIA DRUGS IN AUSTRIA
    Hinteregger, M.
    Fuezi, J.
    Reichardt, B.
    VALUE IN HEALTH, 2013, 16 (07) : A331 - A331
  • [27] Effects of Anti-dementia Drugs on Morphine-Induced Somnolence
    Ishida, Takayuki
    Suga, Asami
    Akagi, Masaaki
    Kamei, Chiaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (11) : 1862 - 1865
  • [28] PRESCRIPTION PATTERNS OF ANTI-DEMENTIA AND PSYCHOTROPIC DRUGS IN PEOPLE LIVING WITH DEMENTIA IN CHINA
    Zhang Yingyang
    Luo, Hao
    Wong, Gloria H. Y.
    Lum, Terry Y. S.
    Chui, Celine
    Wong, Ian C. K.
    Wang, Huali
    INNOVATION IN AGING, 2021, 5 : 646 - 646
  • [29] Lifestyle improvement or anti-dementia drugs in Alzheimer's disease
    Niwa, Fumitoshi
    Mizuno, Toshiki
    Nakagawa, Masanori
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 925 - 925
  • [30] Statistical treatment of withdrawal in trials of anti-dementia drugs - Reply
    Doody, Rachelle
    Seely, Lynn
    Thomas, Ronald
    Sano, Mary
    Aisen, Paul
    LANCET, 2008, 372 (9647): : 1383 - 1383